CHICAGO / Jan 31, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias.
Cardiovascular disease is the leading cause of death globally - affecting millions of individuals and placing a significant burden on healthcare systems today. 1 Within the complex umbrella of cardiology care and cardiovascular disease, atrial fibrillation (AFib) is the most common arrhythmia diagnosed in clinical practice with projections indicating that the prevalence of AFib could reach 15.9 million people in the United States by 2050 and 17.9 million in Europe by 2060.2 For those living with cardiac arrhythmias like AFib, the longer a person is living out of rhythm, the more difficult the arrhythmia is to treat and the more dangerous it may become. If diagnosed early, rhythm control treatment can reduce AFib recurrence and potentially prevent progression.3
Electrophysiology labs play a pivotal role in the treatment of cardiac arrhythmias like AFib and require sophisticated recording systems to capture and analyze intracardiac signals accurately. GE HealthCare’s latest Prucka 3 with CardioLab EP Recording system builds on more than twenty years of success in the field of electrophysiology to provide a robust ecosystem of mapping technologies that help provide accurate, efficient, and advanced analytics for the diagnosis and treatment of cardiac arrhythmias.
The system’s digital platform maintains high signal fidelity, while reducing environmental noise through new signal-filtering capabilities and enhanced software for powerline noise reduction.4 The forward-looking platform also provides a path to emerging technologies in electrophysiology that depend on quality signals for their fast interpretation and clinical results.
“Signal clarity is key in the EP Lab,” shares Dr. Usman Siddiqui, Director of Electrophysiology.5 “With the launch of the latest Prucka 3 digital amplifier, I feel confident analyzing critical signals regardless of the type of ablation technology or platform I am using. Prucka 3 delivers the signal quality I expect from CardioLab and GE HealthCare.”
‘‘The launch of the latest Prucka 3 digital amplifier is a game changer for EP labs,” shares Devon Bream, General Manager of Invasive Cardiology for GE HealthCare. “The new platform not only provides beautiful signals, but the digital architecture continues to demonstrate our commitment to give clinicians the tools, along with the flexibility and adaptability, to enable better outcomes for their patients. After serving the EP community for over 20 years, the latest Prucka 3 with CardioLab truly ‘amplifies’ the EP Lab experience through a fully digital experience ready to enable the future of electrophysiology.”
New features now available as part of the latest Prucka 3 with CardioLab EP Recording system:
Prucka 3 with CardioLab EP Recording system is part of GE HealthCare’s larger cardiology care portfolio to address cardiovascular disease and key challenges faced in cardiology care today. As part of this comprehensive care pathway approach, GE HealthCare has made other recent enhancements to the portfolio including the introduction of Allia IGS Pulse, the next generation of image-guided systems designed for cardiac imaging excellence and CardioVisio for Atrial Fibrillation which helps visualize the history of the patient’s heart and provides guideline-directed insights to healthcare providers.
More about GE HealthCare at AF Symposium 2024
GE HealthCare’s Exhibit Booth 213 will feature opportunities for attendees to interact with the company’s latest innovations, including the Prucka 3 with CardioLab EP Recording system.
Live Case Presentation: On Saturday, February 3rd from 10:00 – 11:00 EST, attendees can view Dr. Saumil Oza, Director of Electrophysiology, perform an Electrogram Dispersion Guided Ablation procedure and present his experiences using Prucka 3 with CardioLab EP Recording System and Volta technology.
“I am excited to highlight GE HeathCare’s latest EP clinical innovation the Prucka 3 digital amplifier at this year’s AF Symposium,” shares Dr. Saumil Oza.6 “EP recording systems and their ability to record clear signals are critical to helping enable advanced technologies in the field of EP.”
For more information on the latest innovations in invasive cardiology, visit https://www.gehealthcare.com/products/invasive-cardiology.
To learn more about GE HealthCare and the company’s comprehensive suite of cardiology solutions, please visit https://www.gehealthcare.com/specialties/cardiology.
This product may not be available in your country or region. Please contact your GE HealthCare representative for more information.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
1 World Health Organization (WHO) estimated 17.9 million people died from cardiovascular diseases in 2019. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2 Vinter N, Huang Q, Fenger-Grøn M, Frost L, Benjamin EJ, Trinquart L. Trends in excess mortality associated with atrial fibrillation over 45 years (Framingham Heart Study): community based cohort study. BMJ. 2020 Aug 11;370:m2724. doi: 10.1136/bmj.m2724. PMID: 32784208; PMCID: PMC7418071.
3 Camm A, Naccarelli G, Mittal S, et al. The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2022 May, 79 (19) 1932–1948. https://doi.org/10.1016/j.jacc.2022.03.337.
4 GE HealthCare Data on File
5 Dr. Siddiqui is a paid consultant for GE HealthCare and was compensated for participation in this testimonial. The statements by Dr. Siddiqui described here are based on his own opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital and many variables exist, (i.e., hospital size, case mix, etc.) there can be no guarantee that other customers will achieve the same results.
6 Dr. Oza is a paid consultant for GE HealthCare and was compensated for participation in this testimonial. The statements by Dr. Oza described here are based on his own opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital and many variables exist, (i.e., hospital size, case mix, etc.) there can be no guarantee that other customers will achieve the same results.
| Last Trade: | US$81.76 |
| Daily Change: | -1.16 -1.40 |
| Daily Volume: | 3,609,013 |
| Market Cap: | US$37.340B |
November 12, 2024 October 30, 2024 October 21, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
